Azithromycin use is associated with an increased risk of death from cardiovascular causes among patients at high baseline risk. Whether azithromycin confers a similar risk in the unselected general ...

In 1982, after investing eight years of effort, Pfizer was preparing to end its work in macrolide research. Its work in finding an improved version of erythromycin had come up empty. But, as happens ...

Azithromycin dosing varies based on the specific bacterial infection being treated, with most adults taking between 500 mg and 2,000 mg depending on whether it’s a single dose or a multi-day regimen.

Azithromycin is an antibiotic that treats many bacterial infections like those in the lungs and skin. It's important to tell ...

Azithromycin can cause side effects that range from mild to serious. More common side effects include nausea, vomiting, and abdominal pain. If azithromycin’s side effects become difficult to tolerate, ...

Empiric azithromycin plus β-lactam therapy reduces the composite risk of 30-day mortality and rehospitalization in nonsevere CAP.

A randomized controlled trial found that patients hospitalized for an acute exacerbation of chronic obstructive poulmonary disease (COPD) experienced reduced rates of treatment failure when adding ...

Azithromycin was effective for the treatment for women with Ureaplasma urealyticum, showing a similar therapeutic effect to that of doxycycline. Results of a systematic review and meta-analysis ...

Azithromycin is a generic drug prescribed for certain bacterial infections. It is available as the brand-name drug Zithromax. Azithromycin’s cost with and without insurance can depend on several ...

Azithromycin for premature newborns requiring breathing support failed to improve rates of survival without moderate or severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age, though it ...

We hypothesized that mass distribution of a broad-spectrum antibiotic agent to preschool children would reduce mortality in areas of sub-Saharan Africa that are currently far from meeting the ...